SCHEMBL13616468

SCHEMBL13616468

C/C=N/N1CCN(Cc2cc(-c3ccc(Cl)cc3)no2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.48
DRD2 P14416 1/20 0.47
DRD4 P21917 1/20 0.47
DRD3 P35462 1/20 0.47
POLB P06746 1/20 0.44
MEN1 O00255 6/20 0.43
KMT2A Q03164 6/20 0.43
L3MBTL1 Q9Y468 4/20 0.43
MAPT P10636 3/20 0.43
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13616496 0.91 NOTUM (0.46) NOTUMDRD2DRD4DRD3POLB
SCHEMBL13616475 0.89 HDAC3 (0.43) POLBMEN1KMT2AL3MBTL1MAPT
SCHEMBL13616471 0.88 DRD2 (0.46) DRD2DRD4DRD3MAPTHDAC3
SCHEMBL13616467 0.88 SMN1; SMN2 (0.47) NOTUMDRD2DRD4DRD3POLB
SCHEMBL13616469 0.88 NOTUM (0.51) NOTUMMEN1KMT2AL3MBTL1MAPT
SCHEMBL13616483 0.87 HDAC3 (0.41) NOTUMDRD2DRD4DRD3MEN1
SCHEMBL13616500 0.87 DRD2 (0.49) NOTUMDRD2DRD4DRD3CXCR1
SCHEMBL13616473 0.86 HDAC3 (0.39) NOTUMDRD2DRD4DRD3MAPT
SCHEMBL13616477 0.86 MAPT (0.49) DRD2DRD4DRD3POLBKMT2A
SCHEMBL13616474 0.85 MAPT (0.43) DRD2DRD4DRD3POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275594-A1 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS JANSSEN PHARMACEUTICA NV (BE) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275594-A1 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS RIF1, ABCC1, HDAC6 NOTUM 4303/4885DRD2 3195/4885DRD4 2082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.